The stock price of Quantum BioPharma Ltd. (NASDAQ: QNTM) had a spectacular increase during the pre-market session, rising 69.46% to $5.39. This dramatic rise comes after a crucial clinical experiment assessing the effectiveness of its dietary supplement, Unbuzzd, in reducing alcohol intoxication and improving alcohol metabolism was successfully concluded.
Innovative Trial Shows Effectiveness
The influence of Unbuzzd on blood alcohol concentration (BAC) and associated intoxication symptoms was evaluated in a recently completed double-blind, randomized, placebo-controlled crossover research. The findings demonstrated that Unbuzzd significantly accelerated the reduction of BAC in study participants while simultaneously alleviating symptoms associated with intoxication and hangovers. All observed effects were statistically significant when compared to the placebo group.
Notably, the benefits of Unbuzzd became apparent within just 30 minutes of consumption. The supplement’s safety profile was confirmed by the fact that it was well tolerated and that no negative effects were noted. Over the course of the four-hour evaluation period, participants’ BAC decrease rates were, on average, more than 40% quicker than those in the control group during the first half hour.
Cognitive and Physiological Benefits Confirmed
Beyond reducing BAC, study participants exhibited statistically significant improvements in mental alertness and cognitive performance within 30 minutes of consuming Unbuzzd. Individuals who took the supplement reported increased focus, enhanced reaction times, and fewer cognitive errors compared to those in the placebo group.
Additionally, Unbuzzd played a critical role in stabilizing physiological responses to alcohol consumption. Participants experienced less fluctuation in heart rate and blood pressure—common effects of intoxication—highlighting the supplement’s potential to mitigate alcohol-related impairments effectively.
A Promising Solution for Responsible Alcohol Consumption
Another key finding from the study was the substantial reduction in hangover severity. Participants who consumed Unbuzzd reported a 67% decrease in headache intensity at the four-hour mark and continued relief at the eight-hour mark. Furthermore, reductions in both cognitive and physical impairment were observed, reinforcing the supplement’s potential benefits for individuals who consume alcohol.
With no reported safety concerns or adverse effects, this clinical study underscores Unbuzzd’s promise as a scientifically backed solution to minimize the adverse effects of alcohol consumption. As consumers seek effective ways to manage intoxication responsibly, Unbuzzd emerges as a significant addition to the landscape of alcohol-related wellness products.